RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Robert L. Copeland to Leukemia, Myeloid, Acute

Back to Details
This is a "connection" page, showing publications Robert L. Copeland has written about Leukemia, Myeloid, Acute.
Robert L. Copeland
Connection Strength
0.119
Leukemia, Myeloid, Acute
  1. Klaus CR, Iwanowicz D, Johnston D, Campbell CA, Smith JJ, Moyer MP, Copeland RA, Olhava EJ, Scott MP, Pollock RM, Daigle SR, Raimondi A. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther. 2014 Sep; 350(3):646-56.
    View in: PubMed
    Score: 0.119
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support